CURE.DE vs. VVSM.DE
CURE.DE (VanEck Genomics and Healthcare Innovators UCITS ETF A) and VVSM.DE (VanEck Semiconductor UCITS ETF) are both exchange-traded funds - CURE.DE is a Health & Biotech Equities fund tracking the MVIS Global Future Healthcare ESG, while VVSM.DE is a Semiconductors fund tracking the MVIS US Listed Semiconductor 10% Capped ESG Index. Both are passively managed. Over the past 3 years, CURE.DE returned -2.48%/yr vs 56.95%/yr for VVSM.DE. At a 0.42 correlation, their price movements are largely independent. Both charge a 0.35% expense ratio.
Performance
CURE.DE vs. VVSM.DE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CURE.DE achieves a -5.10% return, which is significantly lower than VVSM.DE's 86.02% return.
CURE.DE
- 1D
- 4.01%
- 1M
- 6.73%
- YTD
- -5.10%
- 6M
- -8.62%
- 1Y
- 6.04%
- 3Y*
- -2.48%
- 5Y*
- —
- 10Y*
- —
VVSM.DE
- 1D
- -2.77%
- 1M
- 17.60%
- YTD
- 86.02%
- 6M
- 84.42%
- 1Y
- 162.55%
- 3Y*
- 56.95%
- 5Y*
- 38.05%
- 10Y*
- —
CURE.DE vs. VVSM.DE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
CURE.DE VanEck Genomics and Healthcare Innovators UCITS ETF A | -5.10% | 5.09% | 0.30% | -6.42% | -4.35% |
VVSM.DE VanEck Semiconductor UCITS ETF | 86.02% | 33.22% | 31.47% | 70.16% | -8.31% |
Correlation
The correlation between CURE.DE and VVSM.DE is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.34 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.41 |
Correlation (All Time) Calculated using the full available price history since Sep 8, 2022 | 0.42 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CURE.DE vs. VVSM.DE — Risk / Return Rank
CURE.DE
VVSM.DE
CURE.DE vs. VVSM.DE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) and VanEck Semiconductor UCITS ETF (VVSM.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CURE.DE | VVSM.DE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -4.88 | ||
| Sortino ratioReturn per unit of downside risk | -4.74 | ||
| Omega ratioGain probability vs. loss probability | 1.06 | 1.68 | -0.62 |
| Calmar ratioReturn relative to maximum drawdown | 0.30 | 14.16 | -13.86 |
| Martin ratioReturn relative to average drawdown | 0.68 | 48.94 | -48.26 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CURE.DE | VVSM.DE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.29 | 5.17 | -4.88 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 1.21 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.14 | 1.24 | -1.38 |
Drawdowns
CURE.DE vs. VVSM.DE - Drawdown Comparison
The maximum CURE.DE drawdown since its inception was -34.80%, smaller than the maximum VVSM.DE drawdown of -37.64%. Use the drawdown chart below to compare losses from any high point for CURE.DE and VVSM.DE.
Loading charts...
Drawdown Indicators
| CURE.DE | VVSM.DE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -34.80% | -37.64% | +2.84% |
Max Drawdown (1Y)Largest decline over 1 year | -19.07% | -11.65% | -7.42% |
Max Drawdown (3Y)Largest decline over 3 years | -29.32% | -37.53% | +8.21% |
Max Drawdown (5Y)Largest decline over 5 years | — | -37.64% | — |
Current DrawdownCurrent decline from peak | -15.66% | -2.77% | -12.89% |
Average DrawdownAverage peak-to-trough decline | -15.12% | -10.22% | -4.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.53% | 3.38% | +5.15% |
Volatility
CURE.DE vs. VVSM.DE - Volatility Comparison
The current volatility for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) is 5.73%, while VanEck Semiconductor UCITS ETF (VVSM.DE) has a volatility of 12.04%. This indicates that CURE.DE experiences smaller price fluctuations and is considered to be less risky than VVSM.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CURE.DE | VVSM.DE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.73% | 12.04% | -6.31% |
Volatility (6M)Calculated over the trailing 6-month period | 15.20% | 24.35% | -9.15% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.97% | 31.92% | -11.95% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.74% | 31.15% | -10.41% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 20.74% | 30.81% | -10.07% |
CURE.DE vs. VVSM.DE - Expense Ratio Comparison
Both CURE.DE and VVSM.DE have an expense ratio of 0.35%.
Dividends
CURE.DE vs. VVSM.DE - Dividend Comparison
Neither CURE.DE nor VVSM.DE has paid dividends to shareholders.
Frequently Asked Questions
CURE.DE and VVSM.DE have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Both ETFs have the same 0.35% expense ratio. The better choice depends on whether you care most about return, fees, risk, or income.
CURE.DE and VVSM.DE have the same expense ratio: 0.35% per year.
CURE.DE is categorized as Health & Biotech Equities, while VVSM.DE is Semiconductors. CURE.DE tracks MVIS Global Future Healthcare ESG, while VVSM.DE tracks MVIS US Listed Semiconductor 10% Capped ESG Index.
Find the right allocation for CURE.DE and VVSM.DE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer